Azenta, Inc., a global leader in life science solutions, has announced the strategic acquisition of UK Biocentre Limited. This move is set to significantly boost Azenta’s biorepository and sample management infrastructure across Europe, positioning the combined company at the heart of pivotal life sciences workflows in the region.
Azenta UK Ltd., a wholly owned subsidiary of Azenta, completed the purchase of all shares of UK Biocentre Limited on March 4, 2026. The total consideration of GBP 20.5 million includes up to GBP 1.8 million in contingent payments linked to future milestones. UK Biocentre, headquartered in the UK since 2014, generated around GBP 15.3 million in revenue over the last fiscal year and will continue to operate under its established brand.
This acquisition cements Azenta’s ability to deliver comprehensive sample lifecycle solutions in the UK, a crucial research hub, and expands their footprint across Europe. The integration of UK Biocentre with Azenta’s Griesheim, Germany, biorepository will enhance end-to-end services for pharmaceutical, biotech, academic, and public health customers. The partnership is expected to unlock new capabilities, including deployment of cutting-edge, automated sample management technologies such as the 16-million-sample BioArc™ Ultra platform.
Financially, Azenta foresees a modest negative impact on its adjusted EBITDA margin—about 35 basis points in 2026. However, the transaction is forecast to boost organic revenue growth and margin expansion from 2027, supporting previously set targets for long-term financial performance.
Azenta’s leadership underscored that the acquisition builds on their disciplined capital allocation strategy and strengthens their platform for large-scale, automated sample storage and processing. By establishing UK Biocentre as a key European operational hub, Azenta anticipates improved customer reach, enhanced resilience, and expanded infrastructure for advancing scientific research across the continent.
With the acquisition now complete, Azenta and UK Biocentre are poised to accelerate their impact in supporting life-changing research and therapies. UK Biocentre’s established expertise and operational capabilities, combined with Azenta’s global reach and investment in technology, are expected to drive both organizations’ missions forward. The partnership aims to speed up innovation, ensure robust infrastructure, and future-proof capabilities for large-scale biomedical, pharmaceutical, and clinical programs.
Azenta continues to position itself as a leading technology and infrastructure partner for life sciences institutions worldwide, tapping into the growing demand for advanced sample management, biorepository, and multiomics services both in Europe and globally.